Combined SET7/9 and CDK4 inhibition act synergistically against osteosarcoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Osteosarcoma, a common malignant bone tumor, has a poor prognosis due to limited therapeutic options.
• The role of SET7/9 (SET domain-containing lysine-specific methyltransferase 7/9) in osteosarcoma is unclear, hindering its therapeutic potential.
• CDK4 (cyclin-dependent kinase 4) is overexpressed in osteosarcoma and linked to poor patient outcomes.

Purpose of the Study:

• To investigate the role of SET7/9 in osteosarcoma proliferation and its potential as a therapeutic target.
• To explore the mechanistic link between SET7/9, CDK4, and cell cycle regulation in osteosarcoma.
• To evaluate the synergistic effect of combined SET7/9 and CDK4 inhibition as a novel osteosarcoma treatment strategy.

Main Methods:

• SET7/9 inhibition or ablation in osteosarcoma cells.
• Analysis of cell proliferation, cell cycle arrest (G1), and protein interactions (CDK4-cyclin D1).
• In vivo studies evaluating the combination therapy of SET7/9 and CDK4 inhibitors.

Main Results:

• SET7/9 inhibition/ablation suppressed osteosarcoma cell proliferation by inducing G1 arrest.
• SET7/9 inhibition disrupted the CDK4-cyclin D1 interaction, impairing retinoblastoma protein phosphorylation.
• Combined SET7/9 and CDK4 inhibition demonstrated synergistic anti-tumor effects in vivo with reduced dosages.

Conclusions:

• SET7/9 acts as an oncogene in osteosarcoma by regulating the CDK4-cyclin D1 complex.
• Combined SET7/9 and CDK4 inhibition presents a novel, potentially less toxic therapeutic strategy for osteosarcoma.
• Targeting SET7/9 may enhance sensitivity to CDK4 inhibitors, improving osteosarcoma treatment outcomes.